期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

空载树突状细胞注射对荷瘤鼠肿瘤的免疫作用研究

Immunity of unpulsed-dendritic cells in mice with tumor lung metastasis
下载PDF
导出
摘要 目的:研究树突状细胞(DC)不负载肿瘤抗原时对肺部肿瘤的免疫抑制作用。方法:黑色素瘤细胞(MO5)静脉注射诱导同源C57BL/6小鼠肺部转移瘤,鼠趾间分别皮下注射磷酸盐缓冲液、载与未载肿瘤抗原(SI- INFEKEL)的GM-CSF DC,观察对肺肿瘤的免疫抑制作用;并分析其相应的效应细胞。结果:同载有肿瘤抗原的GM-CSF DC一样,未载抗原的GM-CSF DC注射同样对小鼠肺内转移瘤产生了抑制作用[(89.1±6.2)vs(1573.5±23.5),P<0.01]。但作用于用缺乏唾液酸基的单唾液酸四己糖神经节苷脂的抗体(anti-asialo-GM1)治疗后的小鼠则此保护作用消失,而应用anti-CD_8治疗的小鼠则不影响保护作用。结论:空DCs对C57BL/6小鼠肺部转移癌具有很好的保护作用,此保护作用需有NK细胞存在介导。 Objective： To investigate the immunity of unpulsed-dendritic cells （DC） in mice with tumor lung metastases. Methods：Lung metastases in C57BL/6 mice was induced by malignant melanoma MO5 cells injection （iv） that was combined with subcutaneous injection of PBS, unpulsed GM-CSF DCs or GM-CSF DCs plus the tumor antigen SIINFEKEL. Monoclonal-antibody was used to deplete NK or T cells. The immunity and cell response were analyzed. Results： The unpulsed-DCs induced protection against the lung metastases of MO5 cells [ （89.1 ± 6.2） vs （ 1 573.5 ± 23.5 ）, P 〈 0.01 ] similar to that of DCs plus SIINFEKEL. The protection was abrogated by treatment with anti-asialo-GM1 but not by anti-CDs. Conclusion： The subcutaneously injected unpulsed-dendritic cells can protect mice against tumor lung metastases as effective as DCs plus SIINFEKEL, which might be mediated by NK cells.
作者 刘红菊 陶晓南 辛建保 尚丹 熊先智 周琼
机构地区 华中科技大学同济医学院附属协和医院呼吸内科
出处 《中国新药杂志》 CAS CSCD 北大核心 2007年第20期1685-1688,共4页 Chinese Journal of New Drugs
关键词 树突状细胞 自然杀伤细胞 肿瘤抑制 dendritic cell natural kill cell tumor immunity
分类号 R730.3 [医药卫生—肿瘤] R392.1 [医药卫生—免疫学]
  • 相关文献

参考文献13

  • 1罗荣城,尤长宣.肿瘤生物治疗新进展[J].中国新药杂志,2005,14(2):143-146. 被引量：18
  • 2JEFFORD M,MARASKOVSKY E,CEBON J,et al.The use of dendritic cells in cancer therapy[J].Lancet Oncol,2001,2 (6):343-353.
  • 3RODRIGUEZ-LECOMPTE JC,KRUTH S,GYORFFY S,et al.Cell-based cancer gene therapy:breaking tolerance or inducing autoimmunity?[J].Anim Health Res Rev,2004,5 (2):227 -234.
  • 4SURESH K,FRASER G,SCHEID E,et al.Generation of in vitro B-CLL specific HLA class Ⅰ restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate[J].Leuk Lymphoma,2006,47 (2):297-306.
  • 5LANIER L.On guard-activating NK cell receptors[J].Nat Immunol,2001,2(1):23-27.
  • 6LUTZ MB,KUKUTSCH N,OGILVIE AL,et al.An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow[J].J Immunol Methods,1999,223(1):77 -92.
  • 7SPECHT JM,WANG G,DO MT,et al.Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases[J].J Exp Med,1997,186(8):1213-1221.
  • 8GONG J,CHEN D,KASHIWABA M,et al.Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells[J].Nat Med,1997,3 (5):558-561.
  • 9PAWLOWSKA AB,HASHINO S,MCKENNA H,et al.In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice[J].Blood,2001,97 (5):1474-1482.
  • 10YANG S,DARROW TL,VERVAERT CE,et al.Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow[J].Cell Immunol,1997,179 (1):84-95.

二级参考文献15

  • 1Liu Y, Chiriva-Internati M, You C, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-selfcytotoxic T lymphocytes by recombinant adeno-associated virusbased gene loading of dendritic cells [ J ]. Cancer Gene Ther,2005,12(3) :304 - 312.
  • 2Midgley R, Kerr DJ, Mirza N, et al. A phase Ⅱ dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) [J]. Proc Am Soc Clin Oncol,2002,21:23b.
  • 3Chang JWC,Hsieh JJ,Chen J S, et al. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-treated melanoma apoptotic cells for patients with malignant melanoma [ J ]. ProcAm Soc Clin Oncol,2002,21:3b.
  • 4Chiriva-Internati M, Liu Y, Salati E, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells[J ]. Eur J Immunol, 2002,32(1) :30 - 38.
  • 5Slichenmyer WJ,Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases[J]. Semin Oncol, 2001,28 (Suppl 16) :S67 - S79.
  • 6Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as firstline and maintenance therapy for patients with indolent nonhodgkin's lymphoma[J]. J Clin Oncol,2002,20(20):4261 -4267.
  • 7Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer[J]. Clin Colorectal Cancer ,2003,2(4): 246 - 251.
  • 8Goodman L. Persistance-luck-Avastin[J]. J Clin Invest,2004, 113(7) :934 - 940.
  • 9Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastro-intestinal stromal tumors (GIST), an EORTC phase Ⅰ study[J]. Proc Am Soc Clin Oncol,2001,20 : 1 a.
  • 10Fukuora M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839(Iressa) for patients with advanced non-smallcell lung cancer ( IDEAL. 1 ) [ J ]. Proc Am Soc Clin Oncol, 2003,22: 298a.

共引文献17

中国新药杂志
2007年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部